<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PAPER
  SYSTEM "paper-structure-annotation.dtd">
<PAPER><mode2 name="b403534h" hasDoc="yes" version="1153"/><TITLE><s sid="1"><CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/><text>Determination of the <IT>in vivo</IT> pharmacokinetics of palladium-bacteriopheophorbide (WST09) in EMT6 tumour-bearing Balb/c mice using graphite furnace atomic absorption spectroscopy</text></s></TITLE><ABSTRACT><s sid="2"><CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="New" advantage="None"/><text>Palladium-bacteriopheophorbide (WST09), a novel bacteriochlorophyll derivative, is currently being investigated for use as a photodynamic therapy (PDT) drug due to its strong absorption in the near-infrared region and its ability to efficiently generate singlet oxygen when irradiated.</text></s> <s sid="3"><CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/><text>In this study, we determined the pharmacokinetics and tissue distribution of WST09 in female EMT6 tumour-bearing Balb/c mice in order to determine if selective accumulation of this drug occurs in tumour tissue.</text></s> <s sid="4"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>A total of 41 mice were administered WST09 by bolus injection into the tail vein at a dose level of 5.0 ± 0.8 mg kg<SP>−1</SP>.</text></s> <s sid="5"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Three to six mice were sacrificed at each of 0.08, 0.25, 0.5, 1.0, 3.0, 6.0, 9.0, 12, 24, 48, 72, and 96 h post injection, and an additional three control mice were sacrificed without having been administered WST09.</text></s> <s sid="6"><CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="New" advantage="None"/><text>Terminal blood samples as well as liver, skin, muscle, kidney and tumour samples were obtained from each mouse and analyzed for palladium content (from WST09) using graphite furnace atomic absorption spectroscopy (GFAAS).</text></s> <s sid="7"><CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="New" advantage="None"/><text>The representative concentration of WST09 in the plasma and tissues was then calculated.</text></s> <s sid="8"><CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/><text>Biphasic kinetics were observed in the plasma, kidney, and liver with clearance from each of these tissues being relatively rapid.</text></s> <s sid="9"><CoreSc1 atype="GSC" type="Res" conceptID="Res2" novelty="None" advantage="None"/><text>Skin, muscle and tumour did not show any significant accumulation at all time points investigated.</text></s> <s sid="10"><CoreSc1 atype="GSC" type="Res" conceptID="Res3" novelty="None" advantage="None"/><text>No selective drug accumulation was seen in the tumour and normal tissues, relative to plasma.</text></s> <s sid="11"><CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/><text>Thus the results of this study indicate that vascular targeting resulting from WST09 in the circulation, as opposed to selective WST09 accumulation in tumour tissues, may be responsible for PDT effects in tumours that have been observed in other WST09 studies.</text></s></ABSTRACT><BODY><DIV DEPTH="1"><HEADER HEADER_MARKER="1">Introduction</HEADER><P><s sid="12"><CoreSc1 atype="GSC" type="Bac" conceptID="Bac1" novelty="None" advantage="None"/><text>Bacteriochlorophyll-based derivatives are currently being studied as photochemotherapeutic agents, mainly due to their high molar extinction coefficients in the 760 to 780 nm region of the electromagnetic spectrum.<REF TYPE="P" ID="cit1 cit2 cit3">1–3</REF></text></s> <s sid="13"><CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="New" advantage="Yes"/><text>The bacteriochlorophyll-based compounds have further benefits of low toxicity and fast clearance from tissues.</text></s> <s sid="14"><CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="New" advantage="Yes"/><text>This results in little to no risk of dark toxicity or lengthy periods of post treatment photosensitivity, a factor which can be a drawback with Photofrin<SP>®</SP> based photodynamic therapy (PDT).</text></s></P><P><s sid="15"><CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="New" advantage="None"/><text>Palladium bacteriopheophorbide (Fig. 1), code named WST09, is a novel bacteriochlorophyll derivative that is currently in phase II clinical trials for the treatment of recurrent prostate cancer.</text></s></P><P><s sid="16"><CoreSc1 atype="GSC" type="Met" conceptID="Met2" novelty="Old" advantage="None"/><text>To date, investigations concerning the efficacy of WST09-based PDT in <IT>in vivo</IT> tumour therapy have involved irradiation during or immediately following intravenous injection of the WST09 chromophore,<REF TYPE="P" ID="cit4 cit5">4,5</REF> an approach that targets WST09 in the circulation rather than that which might accumulate in tumour tissues at times well after administration such as occurs with other approved PDT drugs.<REF TYPE="P" ID="cit6 cit7 cit8">6–8</REF></text></s> <s sid="17"><CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="New" advantage="Yes"/><text>Results on WST09 have shown high cure rates of mice with prostate small cell carcinoma xenografts,<REF TYPE="P" ID="cit9">9</REF> and PDT treatment data collected so far provide preliminary indications that vasculature targeted PDT is effective with this drug.<REF TYPE="P" ID="cit10 cit11 cit12">10–12</REF></text></s> <s sid="18"><CoreSc1 atype="GSC" type="Mot" conceptID="Mot1" novelty="None" advantage="None"/><text>However the pharmacokinetics of WST09 accumulation and clearance have yet to be reported in an animal tumour model.</text></s></P><P><s sid="19"><CoreSc1 atype="GSC" type="Bac" conceptID="Bac2" novelty="None" advantage="None"/><text>There is mounting evidence that direct cell kill only accounts for about 1 to 2 logs of direct tumour-cell killing,<REF TYPE="P" ID="cit13">13</REF> and that the required 7 to 8 logs of cell kill required for a tumour cure can mostly be related to a microvasculature target as the initial site of injury.</text></s> <s sid="20"><CoreSc1 atype="GSC" type="Mot" conceptID="Mot2" novelty="None" advantage="None"/><text>As a result, knowledge of the time dependent tissue and plasma distribution of WST09 in a tumour-bearing model can elucidate further the mechanism of PDT action of this compound.</text></s> <s sid="21"><CoreSc1 atype="GSC" type="Mot" conceptID="Mot3" novelty="None" advantage="None"/><text>In addition, knowledge of the pharmacokinetic behaviour of this compound provides valuable information pertaining to its potential to elicit skin photosensitivity or systemic toxicity.</text></s></P><P><s sid="22"><CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/><text>In the current study we have determined the <IT>in vivo</IT> pharmacokinetics and tissue distribution of WST09 in an EMT6 tumour-bearing Balb/c mouse model after a single intravenous injection.</text></s> <s sid="23"><CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="New" advantage="None"/><text>The analysis was carried out using a graphite furnace atomic absorption spectroscopy (GFAAS) method in order to selectively detect the Pd in WST09.</text></s> <s sid="24"><CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="New" advantage="Yes"/><text>This is a complementary method to those reported previously for monitoring biological samples containing Pd-organometallics<REF TYPE="P" ID="cit14 cit15 cit16">14–16</REF>.</text></s></P></DIV><DIV DEPTH="1"><HEADER HEADER_MARKER="2">Materials and methods</HEADER><DIV DEPTH="2"><HEADER HEADER_MARKER="2.1">Materials and injection formulation</HEADER><P><s sid="25"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Palladium-bacteriopheophorbide (WST09) was obtained both in powder form and as a 5 mg mL<SP>−1</SP> injection formulation in an alcohol/Cremophor EL<SP>®</SP>/NaOH based proprietary vehicle from Steba Biotech (Toussus-le-Noble, France).</text></s> <s sid="26"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Stock solution was diluted in the solvent in order to obtain a WST09 concentration of 0.5 mg mL<SP>−1</SP> suitable for injection into the mice.</text></s> <s sid="27"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>The stock and diluted solutions were protected from light at all times; the dilutions were performed in dim light conditions and all solution containers were wrapped in aluminum foil.</text></s> <s sid="28"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>The diluted concentrations were verified by measuring the absorbance of WST09 at 758 nm.</text></s></P><P><s sid="29"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>All solvents were commercially available spectroscopic or HPLC grade.</text></s> <s sid="30"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Solvable<SP>®</SP> digestion solution was obtained from Canberra-Packard.</text></s> <s sid="31"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Cremophor EL<SP>®</SP> was obtained from Sigma.</text></s></P></DIV><DIV DEPTH="2"><HEADER HEADER_MARKER="2.2">Animal model</HEADER><P><s sid="32"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>A total of 44 female Balb/c mice were obtained from Charles River, Canada.</text></s> <s sid="33"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>At the time of injection the mice were between 6 and 16 weeks old and had an average body mass of 19.8 ± 1.6 g.</text></s> <s sid="34"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Each mouse carried an EMT6 mammary adenocarcinoma tumour (NCI Frederick Cancer Research and Development Center CDT Tumour Repository).</text></s> <s sid="35"><CoreSc1 atype="GSC" type="Bac" conceptID="Bac3" novelty="None" advantage="None"/><text>This animal/tumour model has been shown in our laboratory to selectively accumulate other Pd-containing drugs suitable for photoactivation.<REF TYPE="P" ID="cit14">14</REF></text></s> <s sid="36"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>The tumours were maintained by serial transplantation of homogenized tumour tissue subdermally into the right flank 3 to 15 days prior to WST09 administration.</text></s> <s sid="37"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Under these conditions, the tumours studied were of roughly equal size, with an average weight at the time of sacrifice of 100 to 150 mg.</text></s> <s sid="38"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Animals were maintained on an <IT>ad libitum</IT> diet of Agribrands Purina Rodent Chow 5001 and tap water.</text></s> <s sid="39"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Animal care was performed in accordance with the guidelines set forth by both the Queens University Animal Care Committee and the Canadian Council for Animal Care.</text></s> <s sid="40"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>All procedures as well as the experimental protocol were peer-reviewed and approved by the Queens University Animal Care Committee prior to the commencement of this study.</text></s></P></DIV><DIV DEPTH="2"><HEADER HEADER_MARKER="2.3">Absorption spectroscopy</HEADER><P><s sid="41"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>The UV-Visible spectra of WST09 dissolved in Solvable<SP>®</SP>, or prepared in injection formulation as described below, were recorded on a UV-Vis spectrophotometer (Shimadzu UV-160, Kyoto, Japan).</text></s></P></DIV><DIV DEPTH="2"><HEADER HEADER_MARKER="2.4">Tissue injection and extraction procedure</HEADER><P><s sid="42"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>The photosensitizer drug was introduced in the mice <IT>via</IT> bolus injections of the WST09 formulation into the tail vein at a dose level of 5.0 ±1.0 mg kg<SP>−1</SP>.</text></s> <s sid="43"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>The mice were kept in the dark, with food and water <IT>ad libitum</IT>, until the time of sacrifice.</text></s> <s sid="44"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Prior to sacrifice the back of each mouse was depilated using Nair<SP>®</SP> Lotion Hair Remover (Carter Horner Corp., Mississauga, Ont., Canada) in order to provide a hairless skin sample; animals were rinsed thoroughly in warm water in order to ensure that all the Nair<SP>®</SP> lotion was removed.</text></s> <s sid="45"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Three to four mice (six in the case of the 1 and 48 h time points) were sacrificed by euthanizing with natural gas (propane) at each of 0.08, 0.25, 0.5, 1.0, 3.0, 6.0, 9.0, 12, 24, 48, 72, and 96 h post injection.</text></s> <s sid="46"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>An additional three mice were sacrificed without having been administered WST09 in order to provide WST09-free baseline values.</text></s> <s sid="47"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Terminal blood samples were obtained <IT>via</IT> cardiac puncture using a syringe coated with 0.1 mL of 3.2% (0.105 M) buffered sodium citrate solution (obtained from a sterile Vacutainer<SP>®</SP> tube, Becton-Dickinson Vacutainer Systems).</text></s> <s sid="48"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>The volume of the blood obtained in each case was noted and the samples were centrifuged for 10 minutes at 2500 rpm at 4 °C.</text></s> <s sid="49"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>100 μL of plasma was then added to 1 mL of Solvable<SP>®</SP>.</text></s> <s sid="50"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Samples of liver, kidney, depilated skin, leg adductor muscle, and tumour were obtained by dissection and rinsed in sterile saline.</text></s> <s sid="51"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>Accurately weighed samples of each tissue were added to Solvable<SP>®</SP> in a volume ratio of 2 mL Solvable<SP>®</SP> per 100 mg of tissue and these, as well as the plasma samples, were placed in a 55 °C oven and allowed to digest for 24 h.</text></s> <s sid="52"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>After digestion, the samples were stored in the dark at room temperature until analysis.</text></s> <s sid="53"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/><text>The entire analysis procedure was carried out under subdued light in order to prevent photodegradation of the WST09.</text></s></P></DIV><DIV DEPTH="2"><HEADER HEADER_MARKER="2.5">Calibration standards</HEADER><P><s sid="54"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/><text>Calibration standards were made by dissolving WST09 in Solvable<SP>®</SP> to obtain a standard solution whose concentration was verified by UV-Vis spectroscopy.</text></s> <s sid="55"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/><text>2 mL calibration standards were then made by adding 100 mg of chicken breast (stored frozen and thawed just prior to use) to appropriate volumes of standard solution and Solvable<SP>®</SP>.</text></s> <s sid="56"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/><text>The standards were placed in a 55 °C lab oven for 24 h in order to allow for complete tissue digestion.</text></s> <s sid="57"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/><text>Calibration standards were used to construct calibration plots during GFAAS analysis.</text></s> <s sid="58"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/><text>Since tissue causes a light scattering effect, the inclusion of tissue in the calibration standards was deemed necessary.</text></s> <s sid="59"><CoreSc1 atype="GSC" type="Met" conceptID="Met3" novelty="Old" advantage="None"/><text>The use of chicken breast to mimic the scattering effect of mouse tissues has been previously validated<REF TYPE="P" ID="cit15">15</REF>.</text></s></P></DIV><DIV DEPTH="2"><HEADER HEADER_MARKER="2.6">Sample stability</HEADER><P><s sid="60"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/><text>In order to check stability, the standards were analysed for palladium content on days 1, 2, 3, and 7 post preparation.</text></s> <s sid="61"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/><text>Standards were stored in the dark, at room temperature for the duration of the study.</text></s> <s sid="62"><CoreSc1 atype="GSC" type="Obs" conceptID="Obs1" novelty="None" advantage="None"/><text>Absorbance peak area of palladium in solutions of 50 mg chicken tissue per mL of Solvable<SP>®</SP> was found to vary linearly with Pd concentration in the region of 5 to 95 ng mL<SP>−1</SP> and the solutions as well as the instrument readings were found to be stable for up to 7 days.</text></s> <s sid="63"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/><text>A calibration curve was obtained each day sample analysis was performed.</text></s></P></DIV><DIV DEPTH="2"><HEADER HEADER_MARKER="2.7">GFAAS analysis</HEADER><P><s sid="64"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/><text>Calibration standards and tissue samples were analyzed using a Unicam 939 Graphite Furnace Atomic Absorption Spectrometer with a Unicam 247.6 nm (palladium atomic absorption line) hollow cathode lamp and a coated, ridged, graphite cuvette.</text></s> <s sid="65"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/><text>A deuterium source was used for background correction and absorbance peak area was measured.</text></s> <s sid="66"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/><text>The coated graphite cuvette was changed every 110 firings because of cuvette aging effects noted during previous method validation.<REF TYPE="P" ID="cit15">15</REF></text></s> <s sid="67"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/><text>Twenty microlitres of unknown sample or calibration standard were injected directly into the graphite cuvette without further preparation.</text></s> <s sid="68"><CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/><text>Three replicate measurements of the absorbance peak area were routinely obtained from each sample, from which the mean absorbance value and standard deviation were obtained.</text></s> <s sid="69"><CoreSc1 atype="GSC" type="Met" conceptID="Met4" novelty="New" advantage="None"/><text>Calibration curves were obtained as described above in order to permit determination of palladium content (ng mL<SP>−1</SP> Solvable<SP>®</SP>) of the unknowns based on the equation of the best linear fit line of the calibration plot.</text></s> <s sid="70"><CoreSc1 atype="GSC" type="Met" conceptID="Met4" novelty="New" advantage="None"/><text>The concentration of palladium (and corresponding concentration of WST09 based on the mass fraction of palladium in WST09) per gram tissue or mL of plasma were then calculated from the concentration of palladium in each sample and known amount of tissue added to the digestion solution (molar ratio of palladium atom to the WST09 macrocycle is 1 ∶ 1).</text></s> <s sid="71"><CoreSc1 atype="GSC" type="Bac" conceptID="Bac4" novelty="None" advantage="None"/><text>The limit of detection of WST09 by this method has been determined elsewhere to be 330 ng g<SP>−1</SP> in skin, 360 ng mL<SP>−1</SP> in plasma, and 610 ng g<SP>−1</SP> in liver, kidney, tumour, and muscle respectively<REF TYPE="P" ID="cit15">15</REF>.</text></s></P></DIV><DIV DEPTH="2"><HEADER HEADER_MARKER="2.8">Determination of pharmacokinetic parameters</HEADER><P><s sid="72"><CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="New" advantage="None"/><text>The mean concentration of WST09 in each tissue was plotted logarithmically <IT>versus</IT> time.</text></s> <s sid="73"><CoreSc1 atype="GSC" type="Mod" conceptID="Mod1" novelty="None" advantage="None"/><text>Assuming a two-compartment open model, the bi-exponential curves that best fit the data were determined using the method of residuals.<REF TYPE="P" ID="cit17">17</REF></text></s> <s sid="74"><CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="New" advantage="None"/><text>In each case, the distribution and elimination rate constants (<IT>k</IT><SB>α</SB> and <IT>k</IT><SB>β</SB>) were obtained graphically from each drug concentration <IT>versus</IT> time plot.</text></s> <s sid="75"><CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="New" advantage="None"/><text>The highest drug concentration observed following administration, and the time at which it is observed (<IT>C</IT><SB>max</SB> and <IT>t</IT><SB>max</SB>), were determined directly from the concentrations measured at each time point.</text></s> <s sid="76"><CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="New" advantage="None"/><text>The area under the drug concentration <IT>versus</IT> time curve, both from time zero to infinity (AUC<SB>0-∞</SB>), and from time zero to the time at which the last quantifiable value was measured (AUC<SB>0-tlast</SB>), were calculated through application of the trapezoidal rule.<REF TYPE="P" ID="cit17">17</REF></text></s> <s sid="77"><CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="New" advantage="None"/><text>Infinity was taken to be the clearance time, or the time at which 99.9% of the initial concentration of the drug was cleared from the tissues (as determined by extrapolation of the terminal elimination phase).</text></s> <s sid="78"><CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="New" advantage="None"/><text>The rate of total clearance of the drug (Cl) was calculated as the dose (μg WST09 injected) divided by the area under the drug concentration <IT>versus</IT> time plot (AUC<SB>0-∞</SB>).</text></s> <s sid="79"><CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="New" advantage="None"/><text>The apparent volume initial distribution (<IT>V</IT><SB>d</SB>) was calculated as the dose (μg WST09 injected) divided by the concentration of WST09 in the plasma when the concentration <IT>versus</IT> time plot was extrapolated back to zero. .</text></s></P></DIV></DIV><DIV DEPTH="1"><HEADER HEADER_MARKER="3">Results and discussion</HEADER><P><s sid="80"><CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="New" advantage="None"/><text>The pharmacokinetic distribution of WST09 in the plasma and tissues at 0.08, 0.25, 0.5, 1.0, 3.0, 6.0, 9.0, 12.0, 24.0, 48.0, 72.0 and 96.0 h post intravenous injection was determined using GFAAS.</text></s> <s sid="81"><CoreSc1 atype="GSC" type="Obs" conceptID="Obs2" novelty="None" advantage="None"/><text>The mean and standard deviation of the concentration of WST09 present in plasma and each tissue at each time point tested are given below in Table 1.</text></s></P><P><s sid="82"><CoreSc1 atype="GSC" type="Res" conceptID="Res2" novelty="None" advantage="None"/><text>WST09 accumulation was not observed in skin, muscle, or tumour at any time.</text></s> <s sid="83"><CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/><text>This lack of accumulation indicates that direct tumour cell kill would not be possible using this drug.</text></s> <s sid="84"><CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/><text>However, local irradiation of the tumour area shortly following iv administration of the drug will potentially target the tumour vasculature.</text></s> <s sid="85"><CoreSc1 atype="GSC" type="Bac" conceptID="Bac5" novelty="None" advantage="None"/><text>This treatment approach has been demonstrated with positive results using bacteriochlorophyll-serine<REF TYPE="P" ID="cit18 cit19">18,19</REF> as well as uncoupled bacteriochlorophyll.<REF TYPE="P" ID="cit3">3</REF></text></s> <s sid="86"><CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/><text>The lack of accumulation in the peritumoural skin and muscle may contribute to the selectivity of the resulting tumour destruction if such a technique is employed, especially if the tumour is the most highly vascularized of the three tissues.</text></s> <s sid="87"><CoreSc1 atype="GSC" type="Con" conceptID="Con3" novelty="None" advantage="None"/><text>The lack of accumulation in the skin also makes unwanted phototoxicity unlikely.</text></s></P><P><s sid="88"><CoreSc1 atype="GSC" type="Obs" conceptID="Obs3" novelty="None" advantage="None"/><text>The level of WST09 in the plasma (Fig. 2) was measured to be maximal (19 μg mL<SP>−1</SP>) at the earliest time point tested, <IT>i.e.</IT> 5 minutes post injection.</text></s> <s sid="89"><CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp1" novelty="None" advantage="None"/><text>Considering the small size of the mouse and the fact that circulation time is rapid, the level of WST09 in the plasma is actually very likely maximized within seconds of the delivery of the bolus dose.</text></s> <s sid="90"><CoreSc1 atype="GSC" type="Obs" conceptID="Obs3" novelty="None" advantage="None"/><text>Furthermore, clearance from the plasma is rapid, with the concentration of WST09 decreasing to zero within three hours of injection.</text></s> <s sid="91"><CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/><text>Therefore, if the vasculature is the intended target, the plasma data support an irradiation time immediately post iv injection of the WST09 in order to take advantage of maximal intravascular concentrations of the drug.</text></s></P><P><s sid="92"><CoreSc1 atype="GSC" type="Obs" conceptID="Obs4" novelty="None" advantage="None"/><text>Initially high levels of WST09 (<IT>C</IT><SB>max</SB> equal to 43 μg g<SP>−1</SP> at 5 minutes post injection) are present in the liver that steadily decrease up to 24 h post injection (Fig. 3).</text></s> <s sid="93"><CoreSc1 atype="GSC" type="Res" conceptID="Res4" novelty="None" advantage="None"/><text>This affinity for the reticuloendothelial organs is typical of lipophilic drugs and represents the binding of the drug to high density lipoprotein (HDL) in the serum and its clearance <IT>via</IT> the bile-gut pathway.<REF TYPE="P" ID="cit20 cit21 cit22 cit23 cit24">20–24</REF></text></s> <s sid="94"><CoreSc1 atype="GSC" type="Obs" conceptID="Obs5" novelty="None" advantage="None"/><text>WST09 is also found to be present in the kidney (<IT>C</IT><SB>max</SB> equal to 8.1 μg g<SP>−1</SP> at 5 minutes post injection) with the levels decreasing to zero at 9 h post injection (Fig. 4).</text></s> <s sid="95"><CoreSc1 atype="GSC" type="Res" conceptID="Res5" novelty="None" advantage="None"/><text>The concentration of WST09 in the kidney is substantially less than that of the liver, consistent with clearance <IT>via</IT> the bile gut pathway.</text></s> <s sid="96"><CoreSc1 atype="GSC" type="Res" conceptID="Res6" novelty="None" advantage="None"/><text>The relatively rapid clearance of the drug from the liver and kidney reduces the risk of unwanted systemic toxicity.</text></s></P><P><s sid="97"><CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/><text>The kinetic results indicate biphasic kinetics for plasma, kidney, and liver.</text></s> <s sid="98"><CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/><text>The existence of a distribution phase in the plasma data was postulated based on only two data points (0.08 and 0.25 h) and therefore the delineation of this phase may be subject to considerable error.</text></s> <s sid="99"><CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp2" novelty="None" advantage="None"/><text>The application of a two-compartment open model was assumed to be correct based on the biphasic kinetics exhibited in the liver and kidney.</text></s> <s sid="100"><CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp2" novelty="None" advantage="None"/><text>However, due to the dynamic equilibrium that exists between the amount of drug present in the plasma and tissues, biphasic kinetics are also expected in the plasma.</text></s> <s sid="101"><CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp2" novelty="None" advantage="None"/><text>Therefore, discounting the existence of the initial fast distribution phase in the plasma would likely have introduced a greater margin of error than that incurred through the determination of the elimination phase using such a small number of data points.</text></s> <s sid="102"><CoreSc1 atype="GSC" type="Mod" conceptID="Mod1" novelty="None" advantage="None"/><text>Analysis of the pharmacokinetic and distribution characteristics in each tissue was performed using a two compartment open model.</text></s> <s sid="103"><CoreSc1 atype="GSC" type="Obs" conceptID="Obs6" novelty="None" advantage="None"/><text>The results of this analysis are shown in Table 2.</text></s></P><P><s sid="104"><CoreSc1 atype="GSC" type="Obs" conceptID="Obs6" novelty="None" advantage="None"/><text>In each of plasma, kidney, and liver, <IT>t</IT><SB>max</SB> was observed at the earliest time point taken, <IT>i.e.</IT>, 5 minutes post injection.</text></s> <s sid="105"><CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/><text>Relatively rapid clearance was observed in plasma, kidney and liver.</text></s> <s sid="106"><CoreSc1 atype="GSC" type="Obs" conceptID="Obs6" novelty="None" advantage="None"/><text>The total rate of clearance and the apparent volume of distribution were calculated to be 11 mL h<SP>−1</SP> and 0.9 mL respectively.</text></s> <s sid="107"><CoreSc1 atype="GSC" type="Res" conceptID="Res7" novelty="None" advantage="None"/><text>This small volume of initial distribution is consistent with the drug initially distributing only within the plasma and blood-rich tissues.</text></s> <s sid="108"><CoreSc1 atype="GSC" type="Res" conceptID="Res7" novelty="None" advantage="None"/><text>This is what was expected based on the lack of drug found in the non-blood-rich tissues, and supports the view that the initial linear portion of the drug concentrations <IT>versus</IT> time curve for plasma was extrapolated correctly despite the small number of data points present.</text></s></P><P><s sid="109"><CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/><text>The goal of this study was the determination of the pharmacokinetic profile of WST09 in an EMT6 tumour-bearing Balb/c mouse model for the purpose of determining its tumour selectivity.</text></s> <s sid="110"><CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/><text>Based on the results obtained by GFAAS, WST09 appears to be efficiently cleared from the plasma and tissues of this model <IT>via</IT> the liver and kidney.</text></s> <s sid="111"><CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/><text>The drug does not appear to accumulate in the skin, muscle, or tumour indicating that vascular targeting is most likely necessary for the effective use of this drug in PDT.</text></s> <s sid="112"><CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/><text>Furthermore, due to the rapid clearance of WST09 from the plasma, irradiation should be carried out immediately after intravenous injection in order to take advantage of maximal intravascular drug concentration.</text></s></P></DIV><DIV DEPTH="1"><HEADER>Abbreviations</HEADER><P><s sid="113"><CoreSc1 atype="GSC" type="Bac" conceptID="Bac6" novelty="None" advantage="None"/><text>GFAAS, graphite furnace atomic absorption spectroscopy; WSTO9/TOOKAD, palladium-bacteriopheophorbide; PDT, photodynamic therapy; AUC<SB>0-tlast</SB>, area under the drug concentration <IT>vs.</IT> time plot from 0 h to the last quantifiable value; AUC<SB>0-∞</SB>, area under the drug concentration <IT>vs.</IT> time plot from 0 h to infinity; Cl, rate of total clearance of the drug; <IT>C</IT><SB>max</SB>, highest drug concentration measured following administration; <IT>k</IT><SB>α</SB>, drug distribution rate constant; <IT>k</IT><SB>β</SB>, drug elimination rate constant; <IT>t</IT><SB>1/2α</SB>, drug distribution half-life; <IT>t</IT><SB>1/2β</SB>, drug elimination half-life; <IT>t</IT><SB>max</SB>, time at which the highest drug concentration is measured following administration; <IT>V</IT><SB>d</SB>, apparent volume of initial drug distribution; IR, infrared; UV-Vis, ultraviolet-visible; HPLC, high pressure liquid chromatography; rpm, revolutions per minute; HDL, high density lipoproteins.</text></s></P></DIV></BODY></PAPER>